Diabetic retinopathy
Conditions
Interventions
Control group:None
Sponsors
Eye Hospital, the First Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 18 years old, positive for serum HCMV-IgG; 2. PDR group: meet the diagnostic criteria (T2DM) in the PDR diagnosis and treatment norms formulated by the Fundus Disease Group of China in 2022; 3. Control group: patients without systemic underlying diseases and without ocular vascular lesions
Exclusion criteria
Exclusion criteria: 1. Autoimmune diseases (systemic lupus erythematosus, systemic sclerosis), tuberculosis, psychiatric diseases, hypertension, atherocerosis patients with sclerosis, AMD, AID, pneumonia, myocarditis and various malignancies and post-transplantation, history of HIV infection, others infectious diseases; 2. Patients with keratitis, uveitis, HCMV retinitis and other ocular vascular/inflammatory diseases in addition to DR; 3. Those with a history of anti-inflammatory, hormone/immunosuppressant therapy, and acute illness in the past 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HCMV nucleic acid fragments;HCMV IgG Antibody; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory cytokine(TNF-?);Inflammatory cytokine(IL-6);Inflammatory cytokine(IL-8);Inflammatory cytokine(IL-18);Inflammatory cytokine(IL-1ß);Inflammatory cytokine(IFN-?);Inflammatory cytokine(ICAM-1);Inflammatory cytokine(VCAM - 1);Inflammatory cytokine(VEGF);Inflammatory cytokine(PEDF);Total IgG Antibody; | — |
Countries
China
Contacts
Public ContactYu Xuhui
Eye Hospital, the First Affiliated Hospital of Harbin Medical University
Outcome results
None listed